The Indian Patent Office has formally granted LTR Pharma Patent No. 605429, titled Formulations and Methods for Treating Erectile Dysfunction. The patent protects defined formulation characteristics of the intranasal technology supporting our SPONTAN® and ROXUS® products, with protection extending to May 2041.
The grant represents a further milestone in our international intellectual property strategy, supporting our ongoing clinical development and commercialisation programs.
LTR Pharma Executive Chairman Lee Rodne said: “The grant of this patent in India is a positive milestone for LTR Pharma, further strengthening the intellectual property portfolio supporting SPONTAN and ROXUS.
“We are pleased with the scope of the granted claims and the additional protection they provide for our intranasal formulation technology.
“Protecting our intellectual property remains an important part of our strategy as we advance our clinical and commercial programs.”